This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Icosavax's Interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults

Ticker(s): ICVX, AZN

Who's the expert?

Institution: Fred Hutchinson Cancer Center

  • Infectious disease physician and researcher who develops mathematical models to address significant medical challenges, assess the potential of a wide variety of potential curative technologies, explain when and how latent viruses reactivate and use models to optimize the effectiveness of antiviral drugs.
  • Major focus of his work is to analyze strategies to achieve an HIV cure and study how T cells help control numerous herpes viruses that cause disease in healthy people and in cancer patients with compromised immune systems.
  • His team also focuses on COVID-19, including developing models of the immune response against the coronavirus and the best treatment strategies

Interview Goal
This interview will focus on the interim results from the Phase 2 clinical trial of IVX-A12, a potential first-in-class combination vaccine candidate against RSV and hMPV.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.